QRFT0.150%
as of Jul 8
REGN
GrowthREGENERON PHARMACEUTICALS INC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
Close · 3M
-14.00%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals2
Win rate0% (0/2)
Avg buy return-6.76%
QRFT · New entry · 1d
weight 0 → 0.180% (new)·stock down 6.3% in the 30 days before
Mar 20·entry $732.87·now $672.15Fresh
-8.29%
since Mar 20
AIEQ · Exit · 1d
Amplify ETFs' AIEQ, leveraging IBM Watson NLP to process news and social posts for daily rankings, removed Regeneron Pharmaceuticals from its portfolio on July 1st. This decision aligns with the fund’s style, which integrates fundamentals and sentiment, as REGN had experienced a notable 90-day return of -20.6% by that point. Such a rapid adjustment reflects the fund's high-turnover nature and daily rebalancing cadence. Watson's continuous analysis, influenced by the ongoing negative price momentum and potentially adverse textual signals, likely downgraded REGN, moving it out of the actively managed 140-180 stock portfolio.
weight 0.320% → 0 (exited)·stock up 4.0% in the 30 days before
Jul 1·entry $624.72·now $672.15
+7.59%
since Jul 1
AIEQ · New entry · 1d
The AI ETF likely added REGN due to its robust 14.83% ROE, indicating strong profitability and efficient management despite its recent flat revenue growth. This signals the AI is prioritizing underlying financial health and potentially future sector catalysts over immediate top-line expansion, suggesting retail investors should similarly evaluate a company's comprehensive financial picture, not just growth figures.
weight 0 → 0.100% (new)·stock down 9.8% in the 30 days before
May 3·entry $709.21·now $672.15Fresh
-5.23%
since May 3
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of May 4
The AI ETF AIEQ recently initiated a new position in Regeneron, signaling a positive outlook on the company's future prospects. This move by the AI contrasts with this framework's finding that Regeneron's long-term cash flows are too unpredictable to model reliably within the defined circle of competence.
- Circle of CompetencePredicting the long-term cash flows of a pharmaceutical company heavily reliant on unpredictable drug development, patent protection, and regulatory outcomes is challenging within a ten-year horizon.
- Economic Moat
- Management
- Financial Health
- Margin of Safety
Regeneron Pharmaceuticals operates in an industry where projecting future cash flows over a ten-year horizon is inherently difficult due to the unpredictable nature of drug development, regulatory approvals, and patent lifecycles. This framework's primary hurdle is the ability to reliably forecast unit economics, which could not be confidently established for REGN. Consequently, the company falls outside the defined circle of competence, preventing further analysis regardless of other potential merits or market price.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.